Q1 Earnings Forecast for ABEO Issued By HC Wainwright

Abeona Therapeutics Inc (NASDAQ:ABEO) – HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Abeona Therapeutics in a report released on Monday, March 24th. HC Wainwright analyst R. Selvaraju expects that the biopharmaceutical company will post earnings per share of ($0.10) for the quarter. HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.05 EPS and FY2026 earnings at ($0.12) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.19.

A number of other equities analysts also recently issued reports on the company. Oppenheimer initiated coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target on the stock. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.

Abeona Therapeutics Trading Down 2.3 %

NASDAQ:ABEO opened at $5.00 on Tuesday. The company has a market cap of $217.36 million, a PE ratio of -1.86 and a beta of 1.79. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The company has a 50 day simple moving average of $5.43 and a two-hundred day simple moving average of $5.82. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $8.45.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ABEO. Twinbeech Capital LP purchased a new stake in Abeona Therapeutics in the fourth quarter worth about $58,000. Squarepoint Ops LLC bought a new position in shares of Abeona Therapeutics during the 4th quarter valued at approximately $67,000. Jane Street Group LLC purchased a new stake in Abeona Therapeutics in the 3rd quarter worth approximately $84,000. Oxford Asset Management LLP purchased a new stake in Abeona Therapeutics in the 4th quarter worth approximately $118,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Abeona Therapeutics during the 3rd quarter worth approximately $151,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.